Actively Recruiting

Phase Not Applicable
Age: 22Years +
All Genders
NCT06134687

Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection

Led by Baylor College of Medicine · Updated on 2026-03-24

66

Participants Needed

2

Research Sites

155 weeks

Total Duration

On this page

Sponsors

B

Baylor College of Medicine

Lead Sponsor

N

Neptune Medical, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this prospective, single centre, 1:1, Post Market, randomized controlled, Investigator Initiated trial, is to compare the feasibility, safety efficacy, and clinical outcomes of colonic endoscopic submucosal dissection (ESD) utilizing a novel rigidizing overtube called Pathfinder® Endoscope Overtube (Neptune Medical, Burlingame California, USA) device in comparison to conventional ESD. The research team hypothesize that with utilizing a novel rigidizing overtube the procedure time including dissection speed and closure time will be faster due to higher scope stability and greater control over the scope tip. Subsequently, the investigators anticipate lower immediate or delayed adverse events.

CONDITIONS

Official Title

Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection

Who Can Participate

Age: 22Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient is 22 years old or older
  • Patients can provide written informed consent
  • Patient is referred for ESD procedure of colonic neoplastic lesions with at least one of the following: A - Lesions with prior resection or scar at any size proximal to the sigmoid colon B - Granular lateral spreading tumors larger than 30 mm C - Non granular lateral spreading tumors larger than 20 mm D - Any suspected submucosal invasion such as Paris classification II a +II or lesions with positive non lifting sign
Not Eligible

You will not qualify if you...

  • Patient refused or is unable to provide written informed consent
  • Patient is pregnant or nursing
  • Lesions with pedunculated morphology (Paris Ip, Ips)
  • Lesions located within the sigmoid colon or rectum
  • Lesions involving the appendiceal orifice or ileocecal valve

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Baylor College of Medicine

Houston, Texas, United States, 77030

Actively Recruiting

2

Baylor St. Lukes Medical Center (BSLMC)

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

M

Michael Mercado, BS

CONTACT

S

Sara Al Yasin, BS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here